🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Larry J. Copeland

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

ORCID: 0000-0001-6204-0962

Also affiliated with The Ohio State University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer”.

Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.06.018
N/A
0.908DataRank · unranked
28 citations

Michael A. Bookman, Jalid Sehouli, Austin Miller, Richard T. Penson, Çağatay Taşkıran +20 more

ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer

International Journal of Gynecological Cancer(2025)10.1016/j.ijgc.2025.101760
N/A
0.449DataRank · unranked
9 citations

Kristin Bixel, Dana M. Chase, Allison Quick, Colleen McCormick, Destin Black +10 more

High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors

Gynecologic Oncology Reports(2022)10.1016/j.gore.2022.101040
N/A
0.312DataRank · unranked
7 citations

David A. Mix Barrington, Morgan Brown, Lynette Gonzalez, Jae Suk Baek, Allison Huffman +10 more

Exploratory evaluation of immunotherapy response and medication use in endometrial and cervical carcinoma

Gynecologic Oncology Reports(2025)10.1016/j.gore.2025.101782
N/A
0DataRank · unranked
0 citations

Molly Morton, Eric McLaughlin, Anna Gonzalez, Jessica Fulton, Jessica Sciuva +11 more

Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial

Nature Communications(2025)10.1038/s41467-024-55200-2
N/A
0DataRank · unranked
18 citations

Dmitriy Zamarin, Wei Deng, Heather A. Lankes, Giulio Pesci, Hayeon Kim +19 more

The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.09.028
N/A
0DataRank · unranked
14 citations

Chunqiao Tian, Joshua P. Kesterson, Michael Richardson, Ken Lin, Krishnansu S. Tewari +14 more

Assessment of readability of gynecologic cancer clinical trials literature at National Cancer Institute–designated Comprehensive Cancer Centers

International Journal of Gynecological Cancer(2025)10.1016/j.ijgc.2025.101693
N/A
0DataRank · unranked
1 citations

Wafa Khadraoui, John L. Hays, Larry J. Copeland, Roberto Vargas, David M. O’Malley +2 more